Rob Bazemore will speak about the vital role that partnering and alliance management have in driving his corporate vision. Collaborations are essential to achieve his multi-year mission and being a partner of choice is one of the six pillars of his strategy. In this session learn the importance of alliance management in supporting partnerships required to launch the company's lead compound, expand its utility and build a robust pipeline. Being a partner of choice is a strategic advantage required for success and alliance management is a critical component in achieving this goal.
Rob will offer his leadership perspective on:
President and Chief Executive Officer
Robert (Rob) Bazemore has served as President and Chief Executive Officer since September 2015. Prior to joining Epizyme, Rob served as Chief Operating Officer of Synageva, where he established the company's global commercial and medical organization to support the first product launch, and helped lead the broader transition to a sustainable commercial enterprise, through its acquisition in July 2015. With more than 25 years of experience across the life sciences industry, Rob held several senior leadership positions at Johnson & Johnson. This included his role as President of Janssen Biotech, where he led the successful launches of numerous products and indications, including the U.S. launches of the oncology therapies ZYTIGA® and IMBRUVICA®, as well as guiding the company's worldwide immunology portfolio strategy. Prior to Johnson & Johnson, he worked at Merck & Co., Inc. for 11 years in roles of increasing responsibility, including the launch of SINGULAIR® in the U.S.
Rob received a B.S. in Biochemistry from the University of Georgia. He currently sits on the Board of Directors of Ardelyx, Inc and Neon Therapeutics.